SLC5A2 and type 2 diabetes mellitus: Due to their cardiovascular benefits, SGLT2 inhibitors are now recommended in the guidelines of key international diabetes associations (including the ADA and EASD) as second-line therapy for patients with T2DM who have established atherosclerotic CVD or high risk for cardiovascular events.